Last reviewed · How we verify

NCT07418775

Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma

Not yet recruiting Last updated 18 February 2026
What this trial tests

trial testing Questionnaire in Meningioma of Brain in 3,000 participants. Not yet recruiting.

Timeline
30 April 2026
Primary endpoint
1 January 2031
1 January 2032

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment3,000
Start date30 April 2026
Primary completion1 January 2031
Estimated completion1 January 2032
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Meningioma of Brain or Meningioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07418775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing